Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2A Double-blind Study of BMS-986435/MYK-224 in HFpEF
jRCT2041250057Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing BMS-986435/MYK-224 with Placebo (2 arms). Primary endpoints: Incidence of treatment emergent adverse events (TEAEs), Incidence of serious adverse events (SAEs) and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
BMS-986435
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on jRCT2041250057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250057.